Initial clinical trials have demonstrated that ciabimatoprost is well-tolerated by patients and shows significant anti-tumor activity. In preclinical models, the drug has been shown to reduce tumor size and improve survival rates. However, more extensive clinical trials are needed to confirm these findings and to establish optimal dosing regimens. Researchers are also investigating the potential for ciabimatoprost to be used in combination with other cancer therapies, such as immunotherapy and radiation therapy.
